This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia (CONNECT)

This study has been terminated.
(Following a pre-specified interim analysis and Data Monitoring Committee recommendation due to insufficient level of efficacy)
Information provided by (Responsible Party):
Sanofi Identifier:
First received: February 22, 2007
Last updated: April 18, 2016
Last verified: April 2016

AVE1625 is a new potent and selective cannabinoid 1 (CB1) antagonist in clinical development for the treatment of cognitive impairment in patients diagnosed with schizophrenia.

The main objective of this study is to evaluate the efficacy on cognitive impairment of 3 doses of AVE1625 using a new cognitive battery called Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) in schizophrenic patients.

The secondary objectives are to measure the efficacy of AVE1625 on functional capacity of the patients using a specific scale called University of California San Diego Performance-based Skills Assessment 2 (UPSA2) and to assess the safety of the compound.

Condition Intervention Phase
Schizophrenia Drug: AVE1625 Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 24-Week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of 3 Oral Doses of AVE1625 and Placebo on Top of Either Olanzapine, Risperidone/Paliperidone, Quetiapine or Aripiprazole in the Treatment of Cognitive Impairment in Schizophrenia.

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Change from baseline in the MATRICS Cognitive Battery composite standardized score [ Time Frame: at week 24 ]

Secondary Outcome Measures:
  • Change from baseline in the UPSA2 total score [ Time Frame: at week 24 ]
  • Additional scales used for schizophrenia [ Time Frame: at week 24 ]
  • Safety: physical examination, vital signs, ECGs, laboratory parameters, adverse events [ Time Frame: study period ]

Enrollment: 873
Study Start Date: February 2007
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: placebo
oral administration
Experimental: AVE1625 dose level 1 Drug: AVE1625
oral administration
Other Name: Drinabant
Experimental: AVE1625 dose level 2 Drug: AVE1625
oral administration
Other Name: Drinabant
Experimental: AVE1625 dose level 3 Drug: AVE1625
oral administration
Other Name: Drinabant


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Outpatients with diagnosis of schizophrenia (diagnosed ≤ 35 years of age).
  • Current treatment consisting exclusively of olanzapine, risperidone/paliperidone, quetiapine or aripiprazole monotherapy for at least 2 months.

Exclusion Criteria:

  • Inpatient hospitalization within past 3 months.
  • Residence at the current address < 3 months due to any instability in the disease.
  • Presence of depressive symptoms.
  • Past history of clinically significant violent behavior.
  • Substance dependence or abuse.
  • Pregnant or breast-feeding women or women not protected by effective contraceptive method of birth control.

The investigator will evaluate whether there are other reasons why a patient may not participate.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00439634

United States, New Jersey
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, United States, 08807
Sanofi-Aventis Administrative Office
Laval, Canada
Sponsors and Collaborators
Study Director: ICD CSD Sanofi
  More Information

Responsible Party: Sanofi Identifier: NCT00439634     History of Changes
Other Study ID Numbers: DRI6726
Study First Received: February 22, 2007
Last Updated: April 18, 2016

Keywords provided by Sanofi:

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders processed this record on September 21, 2017